# Filing Detail

Form DEFR14A - Revised definitive proxy soliciting materials:
SEC Accession No. 0001104659-25-100443
Filing Date
2025-10-17
Accepted
2025-10-17 16:58:10
Documents
6

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFR14A | tm2527643-1_defr14a.htm | DEFR14A | 2755838
2 | GRAPHIC | ic_boardarrow-bw.jpg | GRAPHIC | 1379
3 | GRAPHIC | lg_lavanv-4c.jpg | GRAPHIC | 11821
4 | GRAPHIC | lg_leerinkpartners-4c.jpg | GRAPHIC | 11632
5 | GRAPHIC | px_25lavapy01pg01-bw.jpg | GRAPHIC | 242832
6 | GRAPHIC | px_25lavapy01pg02-4c.jpg | GRAPHIC | 179099
| Complete submission text file | 0001104659-25-100443.txt |  | 3312086

Mailing Address YALELAAN 62 UTRECHT Netherlands
Business Address YALELAAN 62 UTRECHT Netherlands 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: DEFR14A | Act: 34 | File No.: 001-40241 | Film No.: 251401391
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)